Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yaxin Biotechnology is a Shanghai-based biotechnology company focused on the research, development, manufacturing, and commercial supply of animal-origin-free recombinant enzymes and related reagents used in biopharmaceutical production. The company serves bioprocessing, vaccine, cell therapy, mRNA drug, protein sequencing, and IVD workflows with products including recombinant trypsin, recombinant carboxypeptidase B, recombinant enterokinase, recombinant Protein A, nucleases, polymerases, and residual-detection ELISA kits. Yaxin positions itself as a supplier of critical raw materials for biologics manufacturing rather than as a therapeutic drug developer. It operates GMP manufacturing facilities, states that it holds independent intellectual property, and highlights ISO 9001:2015 and ISO 13485:2016 certifications. The company is part of the China National Biotec Group ecosystem and markets itself as a domestic Chinese source of key biopharma raw materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yaxin Biotechnology.